Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $100.00

Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) had its price target boosted by Morgan Stanley from $80.00 to $100.00 in a research report released on Wednesday, Marketbeat Ratings reports. Morgan Stanley currently has an equal weight rating on the biotechnology company’s stock.

Several other analysts have also recently commented on the company. StockNews.com cut Sarepta Therapeutics from a buy rating to a hold rating in a report on Saturday, May 21st. Barclays raised their price target on Sarepta Therapeutics from $104.00 to $125.00 in a report on Wednesday. Oppenheimer raised their price target on Sarepta Therapeutics from $125.00 to $150.00 in a report on Wednesday. Needham & Company LLC raised their price target on Sarepta Therapeutics from $150.00 to $162.00 and gave the company a buy rating in a report on Friday, July 29th. Finally, Cantor Fitzgerald dropped their price objective on Sarepta Therapeutics from $140.00 to $128.00 and set an overweight rating for the company in a research note on Friday, June 24th. Four equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, Sarepta Therapeutics currently has a consensus rating of Moderate Buy and a consensus target price of $126.92.

Sarepta Therapeutics Stock Up 4.5 %

Sarepta Therapeutics stock opened at $106.02 on Wednesday. The company has a current ratio of 4.53, a quick ratio of 5.13 and a debt-to-equity ratio of 1.52. The stock has a 50 day moving average of $78.23 and a two-hundred day moving average of $76.58. The stock has a market capitalization of $9.28 billion, a price-to-earnings ratio of -18.06 and a beta of 1.27. Sarepta Therapeutics has a twelve month low of $61.28 and a twelve month high of $107.03.

Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) last posted its quarterly earnings results on Wednesday, May 4th. The biotechnology company reported ($1.20) EPS for the quarter, beating the consensus estimate of ($1.35) by $0.15. The business had revenue of $210.83 million during the quarter, compared to analysts’ expectations of $208.25 million. Sarepta Therapeutics had a negative return on equity of 67.98% and a negative net margin of 60.66%. The company’s quarterly revenue was up 43.5% compared to the same quarter last year. During the same period last year, the firm earned ($2.10) EPS. As a group, research analysts expect that Sarepta Therapeutics will post -4.48 earnings per share for the current year.

Hedge Funds Weigh In On Sarepta Therapeutics

Hedge funds have recently bought and sold shares of the stock. Exchange Traded Concepts LLC increased its position in Sarepta Therapeutics by 191.7% during the second quarter. Exchange Traded Concepts LLC now owns 633 shares of the biotechnology company’s stock worth $47,000 after buying an additional 416 shares in the last quarter. UMB Bank N A MO purchased a new position in Sarepta Therapeutics during the fourth quarter worth $69,000. IndexIQ Advisors LLC purchased a new position in Sarepta Therapeutics during the first quarter worth $61,000. KRS Capital Management LLC purchased a new position in Sarepta Therapeutics during the fourth quarter worth $96,000. Finally, Laurel Wealth Planning LLC purchased a new position in Sarepta Therapeutics during the first quarter worth $117,000. Hedge funds and other institutional investors own 81.43% of the company’s stock.

About Sarepta Therapeutics

(Get Rating)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.